# 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

> **NCT01237457** · PHASE2 · COMPLETED · sponsor: **Ebrahim S Delpassand** · enrollment: 143 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT01237457
- **Lead sponsor:** Ebrahim S Delpassand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-27
- **Primary completion:** 2016-11-17
- **Final completion:** 2017-07-25
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2023-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237457, "177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01237457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*